Navigation Links
Hologic Announces Third Quarter Fiscal 2013 Operating Results
Date:8/5/2013

en‐Probe revenues in the fourth quarter of fiscal 2013 and, to a lesser extent, the continued ramp‐up of new products including 3D Dimensions, Panther, and MyoSure systems. These increases are partially offset by the elimination of revenues from LIFECODES, which were $7 million (approximately two months) in the fourth quarter of fiscal 2012.
  • The Company expects non‐GAAP adjusted EPS of $0.36 to $0.37. This includes a reduction in EPS of $0.01 from the $6 million charge to earnings to write-off certain deferred financing costs and debt discount in connection with the $200 million voluntary prepayment of the Term B.
  • Fiscal 2013 (Year Ending September 28, 2013):

  • The Company is adjusting its fiscal 2013 non‐GAAP revenues to a range of $2.505 billion to $2.515 billion (from a range of $2.53 billion to $2.55 billion). Year-over-year, this represents an expected increase of 24% to 25% over fiscal 2012 non-GAAP revenues of $2.01 billion, including the $11.6 million purchase accounting adjustment in fiscal 2012.
  • The Company now expects non-GAAP EPS of $1.46 to $1.47 (from $1.54 to $1.56). This revised guidance also includes a $0.01 reduction in EPS in connection with the Term B prepayment discussed above.
  • Hologic may not generate expected revenues and may incur expenses or charges, realize income or gains, or execute acquisitions or dispositions in fiscal 2013 that could cause actual results to vary from the guidance above. In addition, the Company is continuing to monitor the effects of the U.S., European and general worldwide economic and regulatory conditions and related uncertainties, including the implementation of healthcare cost containment measures and healthcare reform legislation, as well as foreign currency fluctuations, which, along with other uncertainties facing the Company's business including those referenced elsewhere herein and its filings with the Securities and Exchange Commission, co
    '/>"/>

    SOURCE Hologic, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

    Related medicine technology :

    1. Hologic Announces Completion of Term Loan B Repricing
    2. FDA Clears Hologics Single Energy Femur Exam to Visualize Features Associated with Developing Atypical Femur Fractures on a DXA Platform
    3. FDA APPROVES APTIMA HPV ASSAY FOR USE ON HOLOGICS PANTHER SYSTEM
    4. Hologic Appoints Jack W. Cumming President and Chief Executive Officer
    5. Commercial Release of 3D (Breast Tomosynthesis) Biopsy Option Strengthens Hologics Position as Provider of the Nations Most Comprehensive Portfolio of Interventional Breast Health Solutions
    6. Quest Diagnostics and Hologic Form Strategic Alliance to Improve Womens Health
    7. Hologic riceve lapprovazione FDA per una nuova soluzione di mammografia 3D (tomosintesi al seno) a bassa dose per lo screening del tumore al seno
    8. Hologic erhält FDA-Zulassung für eine neue niedrigdosierte 3D-Mammographie-Lösung (Brust-Tomosynthese) für Brustkrebs-Screening
    9. First Large-Scale Population-Based Study in the U.S. Shows Hologics 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
    10. Hologic to Present at Three Upcoming Investor Conferences
    11. Hologic Appoints Scott Garrett to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... , NEW YORK and LONDON , ... of market research solutions, MarketResearch.com is pleased to ... Kalorama Information Medical Devices Knowledge Center. ... platform hosting the latest market research in the ... library of reports from industry expert, Kalorama Information, ...
    (Date:8/26/2014)... , Aug. 27, 2014 Higher disposable ... are fuelling the demand for medical devices in ... of medical tourism, the inflow of patients requiring ... market will continue its steady ascent as the ... and non-communicable diseases, compelling significant investments in the ...
    (Date:8/26/2014)... Aug. 26, 2014  Kewaunee Scientific Corporation (Nasdaq: ... quarter ended July 31, 2014. Sales for ... $32,003,000 in the first quarter last year. Net earnings ... share, as compared to net earnings of $1,587,000, or ... the prior year. However, both sales and earnings in ...
    Breaking Medicine Technology:MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 2Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 4Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6
    ... Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication ... June 9 A new analysis demonstrated that ... severely active rheumatoid arthritis (RA) who had prior ... received subcutaneous injections of SIMPONI(TM) (golimumab) once every ...
    ... in June Issue of Circulation , , SILVER ... Corporation (Nasdaq: UTHR ) and Eli Lilly ... the results of a pivotal 16-week study showing that ... improved exercise capacity and improved time to clinical worsening ...
    Cached Medicine Technology:New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 2Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 3Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 4Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 5Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 6
    (Date:8/27/2014)... August 27, 2014 Casey Diekman, assistant ... Technology (NJIT), is helping to gain greater insight into ... life. , Evolution has harmonized the behavior of humans ... that include the cycle of light and dark experienced ... clock controls hormone production related to natural patterns of ...
    (Date:8/27/2014)... California (PRWEB) August 27, 2014 In My ... “Journey Candle Collection” to provide a growing number of women ... scent-based tool for goal setting and relaxing at the same ... soy candles, uses scent memory and visualization to help women ... their life each time they light a candle and enjoy ...
    (Date:8/27/2014)... 2014 PartnerTech Inc ., ... major systems integration and electronics manufacturer, announces a ... the first U.S. designed and manufactured whole body ... combination of manufacturing expertise, location, flexibility, and speed-to-market ... headquartered in Atlanta, GA, offers a whole body ...
    (Date:8/26/2014)... 2014 Hearing aids are not ... for plan holders to determine what their hearing care benefits ... several additional health plans and has published benefit details on ... . , The following is a list of insurances ... provider: , NYSHIP/ NYS Empire Plan - Hearing Aid Benefit ...
    (Date:8/26/2014)... Leelanau Peninsula, MI (PRWEB) August 27, 2014 ... Stompede event is a fabulous time to visit the ... providing a magnificent backdrop to wine tasting fun in ... 7, 2014. , Kicking off the festivities is an ... Saturday at Ciccone Vineyards in Suttons Bay. A unique ...
    Breaking Medicine News(10 mins):Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 2Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 3Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 4Health News:In My Solitude Unveils Eco Candle Line That May Improve Performance 2Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 2Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 3Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 2Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers One-of-a-Kind Walk or Run Through the Vineyards for Walkers, Runners and Wine Tasting Spectators Alike 2Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers One-of-a-Kind Walk or Run Through the Vineyards for Walkers, Runners and Wine Tasting Spectators Alike 3
    ... the latest issue of the journal Antimicrobial Agents and ... occur in the human saliva can lead to new ... in children., ,Researchers at the University of Washington ... between dental caries (tooth decay) prevalence in children and ...
    ... been known to be associated with health hazards ... But it is known not until recently that ... exposure to mineraloil., ,The exact causative factor ... genetic, hormonal factors and environmental fcators have been ...
    ... doubled to 1 million worldwide and tripled in Africa and Asia. ... AIDS. Though, there is a immense increase in antiretroviral // treatment, ... goal to treat 3 million people by 2005, will never happen ... of those in Africa and 14% of those in Asia have ...
    ... control cream and a potent neurotoxin, used by Hollywood ... derived form a bacteria, Clostridium botulinum, that causes food ... this form of neurotoxin is playing an important role ... is exploring basic nerve cell function, minute changes that ...
    ... general health of people. , ,With health consciousness ... for improving health // status has considerably increased. The ... would be dependent to a large scale on the ... plants that the body uses to make vitamin A. ...
    ... teeth, called dentigerous cysts, may be harmless to the tooth ... head and neck area., ,Dentigerous cysts are painless, considered ... tooth eruption. However, head and neck specialists have recently encountered ... neck infections or as a deep neck space abscess. , ...
    Cached Medicine News:Health News:B-Carotene Increases Oral Cancer Risk In Smokers 2Health News:Dental Cysts Can Cause Infections In Head And Neck 2
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    Medicine Products: